A multicentre, randomised trial published in The Lancet Oncology shows that a supervised, behaviourally supported lifestyle programme can measurably blunt the adverse effects of androgen deprivation therapy (ADT) for prostate cancer. Called STAMINA, the study enrolled 700 men on ADT across 15 NHS trusts in England and randomly assigned them in a 5:4 ratio to […]
A new cohort study published in JAMA Network provides some of the most detailed evidence to date on how the type of fat men eat after a prostate cancer diagnosis relates to long-term survival. The analysis, based on 4,884 participants in the Health Professionals Follow-Up Study followed for a median of 12.8 years, shows that […]
IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! No rest for the weekend! Some new promising trials and preclinical research for us. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical […]
For men with metastatic prostate cancer, the current standard is continuous androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach improves survival but comes with substantial clinical and financial toxicity: fatigue, metabolic changes, sexual dysfunction, bone loss, cardiovascular risk, and long‑term treatment costs. The […]
A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]
An exploratory post hoc analysis of the international PEACE‑3 trial adds a compelling biomarker layer to the already positive story of combining radium‑223 with enzalutamide in men with bone‑metastatic, castration‑resistant prostate cancer. The parent study, a phase 3 randomised trial in asymptomatic or mildly symptomatic metastatic castration‑resistant prostate cancer (mCRPC) with bone metastases, had already […]
Neuroendocrine prostate cancer (NEPC) is a highly aggressive, treatment-resistant form of prostate cancer that emerges after androgen-deprivation therapies fail, leaving few effective options. Memorial Sloan Kettering Cancer Center is now running a Phase I trial testing a radiolabeled antibody called 177Lu-DTPA-SC16.56 in patients with progressive, chemotherapy-relapsed neuroendocrine prostate and lung cancers. DLL3 is the reason […]
A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]
Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments […]